Genomic Predictors of Tamoxifen Response in American Male Breast Cancer Patients
Reading Time: 2 minutes Introduction Tamoxifen, a cornerstone in the treatment of hormone receptor-positive breast cancer, has been extensively studied for its efficacy and side effects. While traditionally associated with female patients, an increasing number of American males are diagnosed with breast cancer, necessitating a deeper understanding of how genomic factors influence tamoxifen response in this demographic. This article explores the genomic predictors of tamoxifen response, offering insights into personalized treatment strategies for American male patients. The Role of CYP2D6 in Tamoxifen Metabolism The cytochrome P450 2D6 (CYP2D6) enzyme plays a pivotal role in the metabolism of tamoxifen to its active metabolite, endoxifen. Variations...



